Navigation Links
Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference

HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands, March 11 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia and the Netherlands Cancer Institute will present data from multiple studies at the 2009 St.Gallen Breast Cancer Conference. The St. Gallen Breast Cancer Conference, one of the premiere conferences in breast cancer research worldwide, takes place March 11th-14th, 2009 in St.Gallen, Switzerland.

The study results further underpin the predictive and prognostic power of Agendia's breast cancer recurrence test, MammaPrint(R) and will be discussed at the following poster sessions:

Thursday, 12 March 2009

Poster 0063

Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients (PATH) with Early Stage Breast Cancer

G. Kunz, T. Dimpfl, C. Jakisch, R. Buttner, F. A. de Snoo, O. Krijgsman, E. van Lienen, A. Glas, and R. Bender.

Thursday, 12 March 2009

Poster 0071

The 70 Gene-MammaPrint Profile Allows to Identify a Subgroup of Good-Prognostic Patients with Primary Breast Cancer and 4-9 Positive Lymph Nodes

M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. Glas, I. Eekhout, M. Knauer, and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0072

The 70-gene MammaPrint Prognosis Signature for Optimal Risk Stratification in Endocrine Responsive Breast Cancer

M Knauer, EJT Rutgers, S Mook, F Cardoso, MJ van de Vijver, G Viale, AM Glas, M. Saghatchian, M Kok, JM Bueno-de-Mesquita, SC Linn and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0073

The 70-gene MammaPrint Signature Is Predictive for Chemotherapy Benefit in Early Breast Cancer

M Knauer, ME Sraver, EJT Rutgers, RA Bender, F Cardoso, S Mook, MJ van de Vijver, M. Saghatchian, RHT Koornstra, JM Bueno-de-Mesquita, S Rodenhuis, SC Linn and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0074

Early Prognosis Prediction: MammaPrint on Core-needle biopsies

F. de Snoo, A. Glas, A. Floore, J. Mayordomo, A. Modollel, C. Rolfo, LJ van 't Veer, E. Rutgers, S. Rodenhuis, and R. Bender.

Thursday, 12 March 2009

Poster 0075

Use of the Genomic Test MammaPrint in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients

G. Kunz, A. Glas and F. de Snoo, I. Simon.

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test result provides a doctor with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
2. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
3. Agendia Appoints VP of Business Development
4. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
5. Agendia Appoints New Chief Financial Officer
6. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
9. Agendia BV Appoints Clinical and Scientific Advisory Board
10. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Post Your Comments:
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential micronutrient ... to proteins, copper is also toxic to cells. With a $1.3 million award ... will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):